COR Stock Recent News

Cencora, Inc COR on Wednesday reported second-quarter 2025 sales increased 10.3% to $75.5 billion, missing the consensus of $75.68 billion, primarily due to an 11.4% increase in revenue within the U.S. Healthcare Solutions segment.

Cencora, Inc. (NYSE:COR ) Q2 2025 Earnings Conference Call May 7, 2025 8:30 AM ET Company Participants Bennett Murphy - Senior Vice President, Head of Investor Relations & Treasury Bob Mauch - President & Chief Executive Officer Jim Cleary - Executive Vice President & Chief Financial Officer Conference Call Participants Elizabeth Anderson - Evercore ISI Michael Cherny - Leerink Capital Lisa Gill - JPMorgan George Hill - Deutsche Bank Charles Rhyee - TD Cowen Eric Percher - Nephron Research Steven Valiquette - Mizuho Securities Allen Lutz - Bank of America Daniel Grosslight - Citi Kevin Caliendo - UBS Erin Wright - Morgan Stanley Operator Hello, everyone, and thank you for joining the Cencora Fiscal 2025 Second Quarter Results Conference Call. My name is Lucy, and I will be coordinating your call today.

Cencora (COR) came out with quarterly earnings of $4.42 per share, beating the Zacks Consensus Estimate of $4.08 per share. This compares to earnings of $3.80 per share a year ago.

U.S. drug distributor Cencora raised its annual profit forecast on Wednesday, driven by robust demand for costly specialty medicines and weight-loss drugs.

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) reported that in its fiscal year 2025 second quarter ended March 31, 2025, revenue increased 10.3 percent year-over-year to $75.5 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $3.68 for the second quarter of fiscal 2025 compared to $2.09 in the prior year second quarter. Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below.

The medical device sector saw steady sales growth in the first quarter of 2025, supported by innovation in AI, wearables, and personalized care. However, earnings gains were more modest as global tariffs, inflationary costs, and supply chain disruptions continued to pressure margins.

VANCOUVER, BC / ACCESS Newswire / May 6, 2025 / Camino Minerals Corporation (TSXV:COR)(OTC PINK:CAMZF) (WKN: A116E1) ("Camino" or the "Company") is pleased to announce exploration results at its Copper-Silver stratabound Los Chapitos copper project ("Los Chapitos" or the "Project"), including drilling and additional mapping, trenching, and sampling along both the La Estancia and Diva copper mineralized trends. The Company is targeting large-scale disseminated manto-type copper-silver mineralization to support resource delineation studies at Los Chapitos.

COR's fiscal second-quarter results are likely to reflect decent U.S. Healthcare Solutions segmental performance.

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Cencora (COR), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2025.

Cencora (COR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.